<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">03385</article-id><article-id pub-id-type="doi">10.7554/eLife.03385</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-15061"><name><surname>Lew</surname><given-names>Erin D</given-names></name><aff><addr-line><named-content content-type="department">Molecular Neurobiology Laboratory</named-content></addr-line>, <institution>The Salk Institute for Biological Studies</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15062"><name><surname>Oh</surname><given-names>Jennifer</given-names></name><aff><addr-line><named-content content-type="department">Molecular Neurobiology Laboratory</named-content></addr-line>, <institution>The Salk Institute for Biological Studies</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15063"><name><surname>Burrola</surname><given-names>Patrick G</given-names></name><aff><addr-line><named-content content-type="department">Molecular Neurobiology Laboratory</named-content></addr-line>, <institution>The Salk Institute for Biological Studies</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15065"><name><surname>Lax</surname><given-names>Irit</given-names></name><aff><addr-line><named-content content-type="department">Department of Pharmacology</named-content></addr-line>, <institution>Yale University School of Medicine</institution>, <addr-line><named-content content-type="city">New Haven, CT</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-19460"><name><surname>Zagórska</surname><given-names>Anna</given-names></name><aff><addr-line><named-content content-type="department">Molecular Neurobiology Laboratory</named-content></addr-line>, <institution>The Salk Institute for Biological Studies</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18346"><name><surname>Través</surname><given-names>Paqui G</given-names></name><aff><addr-line><named-content content-type="department">Molecular Neurobiology Laboratory</named-content></addr-line>, <institution>The Salk Institute for Biological Studies</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15066"><name><surname>Schelssinger</surname><given-names>Joseph</given-names></name><aff><addr-line><named-content content-type="department">Department of Pharmacology</named-content></addr-line>, <institution>Yale University School of Medicine</institution>, <addr-line><named-content content-type="city">New Haven</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-12043"><name><surname>Lemke</surname><given-names>Greg</given-names></name><aff><addr-line><named-content content-type="department">Molecular Neurobiology Laboratory</named-content></addr-line>, <institution>The Salk Institute for Biological Studies</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country><email>lemke@salk.edu</email></aff><xref ref-type="fn" rid="conf4"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-12145"><name><surname>Goff</surname><given-names>Stephen P</given-names></name><role>Reviewing editor</role><aff><institution>Howard Hughes Medical Institute, Columbia University</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>29</day><month>09</month><year>2014</year></pub-date><volume>3</volume><elocation-id>e03385</elocation-id><supplementary-material><ext-link xlink:href="elife-03385-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>15</day><month>05</month><year>2014</year></date><date date-type="accepted"><day>28</day><month>09</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014, Lew et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Lew et al</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>The TAM receptor tyrosine kinases Tyro3, Axl, and Mer regulate key features of cellular physiology, yet the differential activities of the TAM ligands Gas6 and Protein S are poorly understood. We have used biochemical and genetic analyses to delineate the rules for TAM receptor-ligand engagement, and find that the TAMs segregate into two groups based on ligand specificity, regulation by phosphatidylserine, and function. Tyro3 and Mer are activated by both ligands, but only Gas6 activates Axl. Optimal TAM signaling requires coincident TAM ligand engagement of both its receptor and the phospholipid phosphatidylserine (PtdSer): Gas6 lacking its PtdSer-binding 'Gla domain' is significantly weakened as a Tyro3/Mer agonist and is inert as an Axl agonist, even though it binds to Axl with wild-type affinity. In two settings of TAM-dependent homeostatic phagocytosis, Mer plays a predominant role while Axl is dispensable, and activation of Mer by Protein S is sufficient to drive phagocytosis.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Irit Lax, is a shareholder in Kolltan Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf3"><p>Joseph Schelssinger, is a shareholder in Kolltan Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf4"><p>Greg Lemke, is a shareholder in Kolltan Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocol of the Salk Institute, Animal Use Protocol No. 11-00051, approval date of record June 3, 2014.</p></fn></fn-group></back></article>